Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its biosimilar version of Novo Nordisk’s Victoza (liraglutide). This new biosimilar is intended for use in treating patients with type 2 diabetes.
Liraglutide Biosimilar: A Milestone in Diabetes Treatment
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, plays a crucial role in improving blood sugar control for individuals with type 2 diabetes. Huadong’s biosimilar version of liraglutide marks a significant advancement as it is the first of its kind in China. This approval not only expands access to a crucial diabetes treatment but also reflects the company’s commitment to bringing affordable and effective therapies to the market.
Potential Obesity Treatment and Market Impact
Huadong’s biosimilar liraglutide is also awaiting regulatory decisions for its use as a treatment for obesity in China. If approved, Huadong would become the first domestic company to gain approval for liraglutide in the treatment of obesity and overweight, further diversifying the drug’s application and potentially transforming the landscape of weight management treatments in the country.-Fineline Info & Tech
